AbbVie has pegged multibillion-dollar hopes on Rinvoq to fill the revenue gap when immunology superstar Humira loses U.S. market exclusivity. But that plan, dependent on multiple label expansions, has hit its second regulatory setback in weeks.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,